MRK vs PYXS · P/E 33, rev $16.61B vs rev $2.8M
Merck & Company Inc (MRK) versus Pyxis Oncology Inc (PYXS) — a side-by-side from cached financials, not a winner call.
Merck & Company Inc (MRK) is a drug manufacturers - general company listed on NYSE. It is led by Rob Davis.
Pyxis Oncology Inc (PYXS) is a biotechnology company listed on NASDAQ.
Latest reported MRK revenue for 2026-06-30 was $16.61B. Net income was -$1.33B. Revenue was up 2.0% from 2026-03-31 to 2026-06-30. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
Latest reported PYXS revenue for 2025-09-30 was $2.8M. Net income was -$22.0M. Revenue was up 0.0% from 2025-06-30 to 2025-09-30. PYXS currently screens at market cap $109.6M.
MRK currently screens at market cap $285.12B and trailing P/E 32.5. PYXS currently screens at market cap $109.6M.
Not investment advice. Open the MRK and PYXS stock pages for the full models.
Not investment advice.